Business Context and Reporting Period
Company: Acasti Pharma Inc. (Note: Request metadata listed "Grace Therapeutics," but the filing text identifies the registrant as Acasti Pharma Inc.)
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended February 28, 2014
Business Overview: Acasti is an emerging biopharmaceutical company focused on developing krill oil-based omega-3 phospholipid therapies. Its primary prescription drug candidate, CaPre, is in clinical development for the treatment of hypertriglyceridemia. Its only commercialized product is ONEMIA, a medical food. The company is a subsidiary of Neptune Technologies & Bioressources Inc.
Key Financial Metrics
| Metric | Fiscal 2014 | Fiscal 2013 | Fiscal 2012 |
|---|---|---|---|
| Revenue from Sales | $500,875 | $724,196 | $10,415 |
| Gross Profit | $209,022 | $317,825 | $5,338 |
| Gross Margin | 42% | 44% | 51% |
| Net Loss | $(11,611,649) | $(6,892,360) | $(6,500,933) |
| Loss Per Share (Basic/Diluted) | $(0.14) | $(0.09) | $(0.10) |
| Total Assets | $45,631,803 | $12,170,048 | $15,728,860 |
| Cash and Short-Term Investments | $23,701,441 | $4,784,795 | N/A |
| Total Liabilities | $12,352,303 | $2,446,372 | $1,259,518 |
| Share Capital | $61,027,307 | $28,922,710 | $28,614,550 |
Note: All figures are in Canadian Dollars (CAD) unless otherwise specified. The significant increase in Total Assets and Share Capital in 2014 is primarily due to equity financings and the capitalization of a royalty prepayment.
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased by approximately 31% to $501,000 from $724,000 in the prior year. This decline is attributed to the company's reliance on a limited number of distributors and the increased cost of raw materials following the destruction of its parent company's production plant.
- Increased Net Loss: Net loss widened to $11.6 million from $6.9 million. Drivers include increased Research and Development (R&D) expenses for clinical trials, higher stock-based compensation, and significant amortization of the intangible asset acquired via the royalty prepayment agreement.
- Liquidity Improvement: Cash and short-term investments surged to approximately $23.7 million from $4.8 million, driven by a public offering of 18.4 million units (gross proceeds ~$23 million USD) and a private placement in late 2013/early 2014.
- Derivative Liabilities: A new liability of $11.2 million was recorded for derivative warrant liabilities arising from the public offering, as the exercise price currency differed from the functional currency.
Guidance, Outlook, and Risks
Outlook and Management Commentary
- Clinical Progress: The company completed the Phase II COLT trial with positive results showing triglyceride reductions. The Phase II TRIFECTA trial is ongoing with results expected in the first half of 2014. An Investigational New Drug (IND) application for a Pharmacokinetic (PK) trial in the U.S. was cleared by the FDA in January 2014.
- Strategic Shift: Due to FDA feedback regarding competitor approvals, the company is reassessing its strategy to potentially focus primarily on the severe hypertriglyceridemia population for its Phase III trial.
- Capital Allocation: Proceeds from recent financings are allocated to completing the TRIFECTA trial, initiating the PK trial, funding a Phase III trial, and conducting required nonclinical studies (DART and CARCINO).
Risks and Contingencies
- Executive Litigation: On May 29, 2014, former CEO Henri Harland filed a lawsuit against the company and its parent, alleging constructive dismissal and seeking approximately $8.5 million in damages plus equity awards. The company intends to vigorously defend the claim.
- Supply Chain Disruption: The parent company's production plant was destroyed by fire in 2012. While reconstruction is underway, the company currently sources krill oil from the open market, creating risks regarding cost, quality, and supply continuity.
- Regulatory Uncertainty: Commercialization depends entirely on the success of CaPre's clinical trials and FDA approval, which is not expected until 2016 at the earliest.
- Profitability: The company has an accumulated deficit of approximately $31.7 million and expects to continue incurring substantial losses for the foreseeable future.
Investor Verification Checklist
- Executive Departure: Verify the status of the lawsuit filed by former CEO Henri Harland and its potential financial impact.
- Supply Chain: Confirm the timeline for the parent company's plant reconstruction and the terms of interim krill oil supply agreements.
- Clinical Milestones: Monitor the release of final results for the TRIFECTA Phase II trial and the initiation of the U.S. PK trial.
- Cash Burn Rate: Assess whether the $23.7 million cash balance is sufficient to fund operations through the planned Phase III trial without further dilution.
- Derivative Liability: Review the valuation assumptions for the $11.2 million derivative warrant liability, as changes in fair value impact net income.